NAGE Niagen Bioscience, Inc.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1386570 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-1.9%
TTM net income YoY-49.9%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR13.6%
Net income 3-yr CAGR—
Margins
Gross margin63.9%
Operating margin3.9%
Net margin8.4%
FCF margin—
EBITDA margin4.3%
Returns
ROE13.3%
ROA9.9%
ROIC (approx.)44.3%
Asset turnover1.18x
Leverage & solvency
Liabilities / assets23.6%
Debt / equity0.00x
Current ratio5.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.48x
Accruals ratio5.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $129.42M | $99.60M | $83.57M | $72.05M | $67.45M |
| Cost of revenue | $46.23M | $38.01M | $32.79M | $29.25M | $25.96M |
| Gross profit | $83.19M | $61.59M | $50.78M | $42.80M | $41.49M |
| R&D expense | $6.33M | $6.02M | $4.96M | $4.83M | $3.83M |
| SG&A expense | $27.06M | $18.38M | $24.98M | $28.29M | $36.38M |
| Operating income | $16.28M | $7.73M | -$5.60M | -$18.63M | -$27.07M |
| Interest expense | — | — | — | — | $55,000 |
| Pretax income | $18.19M | $8.86M | -$4.94M | — | — |
| Income tax | $810,000 | $305,000 | $0 | — | — |
| Net income | $17.38M | $8.55M | -$4.94M | -$16.54M | -$27.13M |
| EBITDA | $16.89M | $8.39M | -$4.73M | -$17.76M | -$26.18M |
| EPS (basic) | 0.22 | 0.11 | -0.07 | -0.24 | -0.40 |
| EPS (diluted) | 0.20 | 0.11 | -0.07 | -0.24 | -0.40 |
| Weighted avg. shares (diluted) | 85.44M | 78.12M | 74.98M | 69.73M | 67.19M |
| Banking | |||||
| Net interest income | — | — | $661,000 | $3,000 | -$55,000 |
| Balance sheet | |||||
| Cash & equivalents | $64.79M | $44.66M | $27.32M | $20.44M | $28.22M |
| Receivables | $9.74M | $7.77M | $5.23M | $8.48M | $5.23M |
| Inventory | $20.42M | $9.19M | $14.53M | $14.68M | $13.60M |
| Current assets | $96.81M | $64.10M | $49.53M | $46.57M | $48.91M |
| PP&E, net | $1.32M | $1.72M | $2.14M | $2.80M | $3.00M |
| Intangibles | $5.66M | $359,000 | $510,000 | $671,000 | $857,000 |
| Total assets | $106.41M | $68.28M | $54.96M | $54.06M | $57.84M |
| Current liabilities | $19.92M | $17.95M | $20.62M | $17.87M | $17.61M |
| Total liabilities | $29.87M | $22.18M | $26.51M | $25.39M | $26.11M |
| Shareholders' equity | $76.53M | $46.09M | $28.46M | $28.67M | $31.73M |
| Shares outstanding | 79.71M | 77.33M | 74.98M | 74.57M | 68.13M |
| Cash flow statement | |||||
| Operating cash flow | $13.50M | $12.11M | $7.12M | -$15.10M | -$24.16M |
| Investing cash flow | -$292,000 | -$143,000 | -$143,000 | -$334,000 | -$409,000 |
| Financing cash flow | $6.92M | $5.37M | -$90,000 | $7.65M | $36.09M |
| Depreciation & amortization | $612,000 | $663,000 | $870,000 | $869,000 | $890,000 |
| Stock-based compensation | $6.07M | $3.66M | $4.75M | $5.74M | $6.20M |
| Share buybacks | $251,000 | $0 | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.